

RECEIVED
CENTRAL FAX CENTER

OCT 22 2004

Attorney Docket No.: 5367.230-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Knudsen et al

Serial No.: 10/730,215

Group Art Unit: 1636

Filed: December 8, 2003

Examiner: McKelvey, Terry Alan

For: GLP-2 Derivatives

**CERTIFICATE OF FACSIMILE TRANSMISSION
703-872-9306**

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:


I hereby certify that the attached correspondence comprising:

1. Response to Restriction Requirement and Amendment

was sent to the United States Patent and Trademark Office by telefax to the attention of Examiner Terry Alan McKelvey, fax number (703) 872-9306.

Respectfully submitted,

Date: October 22, 2004


Csaba Attila Szakolczai
Novo Nordisk® Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800

RECEIVED
CENTRAL FAX CENTER

OCT 22 2004

PATENT
Attorney Docket No. 5367.230-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Knudsen et al.

Application No. 10/730,215

Filed: December 8, 2003

For: GLP-2 DERIVATIVES

Group Art Unit: 1636

Examiner: McKelvey, Terry Alan

RESPONSE TO RESTRICTION REQUIREMENT AND AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In response to the Office Action mailed September 29, 2004, please amend the above-referenced application and consider the provided remarks as follows:

Amendments to the Claims are reflected in the **Listing of Claims**, which begins on page 2 of this paper.

Remarks concerning the Office Action and the claim amendments begin on page 6 of this paper.